Statute Details
- Title: Medicines (Labelling of Chinese Proprietary Medicines) Regulations
- Act Code: MA1975-RG13
- Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act (Chapter 176, Sections 44, 45, 46 and 52)
- Regulation Number: Rg 13
- Gazette Citation: G.N. No. S 494/1998
- Revised Edition: 2005 (31 March 2005)
- Current Version Status: Current version as at 27 Mar 2026
- Key Provisions (from extract): Regulation 2 (definitions); Regulation 2A (scope/exclusion); Regulation 3 (mandatory particulars); Regulation 5 (substances in Schedule); Regulation 6 (prohibited claims/leaflets)
- Schedule: Substances to be labelled (with required English statements)
What Is This Legislation About?
The Medicines (Labelling of Chinese Proprietary Medicines) Regulations (“the Regulations”) set out Singapore’s rules for how Chinese proprietary medicines must be labelled and what information must be provided to consumers at the point of sale or supply. In practical terms, the Regulations aim to ensure that buyers can identify the product, understand key safety and use information, and are not misled by prohibited therapeutic claims.
Chinese proprietary medicines are a category of traditional medicines regulated under Singapore’s broader medicines framework. This particular set of Regulations focuses narrowly on labelling: what must appear on the container, any outer package, and any leaflet supplied with the medicine. It also regulates the content of labels and leaflets—especially by restricting claims that would imply disease prevention, alleviation, or cure for specified diseases or conditions.
The Regulations are designed to be operational for manufacturers, wholesalers, importers, and retailers. They create clear compliance duties: if the required particulars are missing or if prohibited claims appear, the medicine cannot lawfully be sold or supplied. This makes the Regulations particularly relevant for legal review of packaging, artwork, product inserts, and distribution practices.
What Are the Key Provisions?
1. Definitions and interpretive framework (Regulation 2)
The Regulations define key terms that drive compliance. Two definitions are especially important for labelling accuracy:
- “appropriate non-proprietary name”: This is the name of the Chinese proprietary medicine or ingredient as stipulated in approved Chinese materia medica references (for example, “A Dictionary of Chinese Pharmacy” (中药大辞典) or “The Chinese Herbal Medicine Materia Medica” (本草纲目)), or such other publication as may be approved by the Minister. Alternatively, it may be the accepted scientific name or another descriptive name of the true nature of the medicine/ingredient.
- “appropriate quantitative particulars”: This requires quantitative ingredient information in each dosage unit (or, where there is no dosage unit, the quantity of each active ingredient), expressed in weight/volume/capacity/units of activity, or as a percentage by weight or volume of the total quantity.
These definitions matter because the Regulations do not permit “marketing names” to replace the required non-proprietary names and quantities. For practitioners, this is a common source of non-compliance when labels use brand-style ingredient names or omit quantitative ingredient data.
2. Scope and exclusion for clinical research materials (Regulation 2A)
Regulation 2A provides that the Regulations do not apply to any Chinese proprietary medicine that is clinical research material as defined under the Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016. This carve-out recognises that clinical research packaging and documentation are governed by a separate regulatory regime, typically involving trial protocols and controlled information flows.
3. Mandatory particulars on container, package, and leaflet (Regulation 3)
The core compliance obligation is in Regulation 3. Subject to the Regulations, no person may sell or supply a Chinese proprietary medicine unless the required particulars are stated in the correct places:
- Container: must be labelled with specified particulars.
- Immediate package (where the container is enclosed): must be labelled with additional required particulars.
- Leaflet (where supplied): must include certain usage and safety information.
Regulation 3(2) lists the particulars. Key items include:
- Trade/brand name under which the medicine is sold.
- Appropriate non-proprietary name of the medicine.
- Batch reference given by the manufacturer.
- “Date after which … should not be used” (expiry/validity concept).
- Wholesaler name and address (or importer name/address if imported).
- Manufacturer name and address (including country of manufacture).
- Assembler name/address (if applicable).
- Appropriate non-proprietary names of ingredients.
- Appropriate quantitative particulars of ingredients.
- Recommended dosage.
- Purpose(s) for which it is to be used.
- Purpose(s) for which it should not be used.
- Possible side effects.
- Directions for use, including time and method of administration.
Practical compliance points: The Regulations are structured so that the “where” and “what” are both legally significant. If a leaflet is not supplied, certain particulars must appear on the container or package instead (see Regulation 3(6) in the extract). Conversely, if a leaflet is supplied, the leaflet must carry the specified usage/safety particulars.
4. Exceptions for secret/protected formulas (Regulation 3(3))
Regulation 3(3) provides a limited exception to the requirement to state ingredient names and quantitative particulars (Regulation 3(2)(h) and (i)). The exception applies where:
- It is proved to the satisfaction of the Minister that the formula has been certified by the relevant health authority of the country of manufacture as a secret or protected formula; or
- Where the manufacturing country does not certify secret/protected formulae, the Minister is satisfied that the formula is secret or protected.
This is a high-stakes area for legal review because it requires evidence and Ministerial satisfaction. Practitioners should treat this as an evidentiary and regulatory approval pathway rather than a simple packaging discretion.
5. Small container and no-package/no-leaflet scenarios (Regulation 3(4)–(6))
Regulation 3 also anticipates real-world packaging constraints:
- Too-small containers: where there is insufficient space to state ingredient names/quantities, the label must state what it can, following the order of particulars in Regulation 3(2), and the remaining particulars must appear on the immediate package.
- No package: if sold without any package, certain particulars (notably wholesaler/importer, manufacturer, and assembler) must be on the container.
- No leaflet: if sold without a leaflet, certain usage and safety particulars must be stated on the container or package (and can be in any order).
6. Substances specified in the Schedule must be labelled in English (Regulation 5)
Regulation 5 prohibits sale/supply of a Chinese proprietary medicine containing any substance listed in the Schedule unless the container (and any immediate package) bears an English statement declaring the presence of that substance. The statement may describe the substance using a corresponding term specified in the Schedule or an equivalent term.
This provision is significant for cross-border compliance and consumer transparency. It also creates a clear “trigger”: if the product contains a Schedule substance, the English declaration is mandatory. Practitioners should ensure ingredient lists and formulations are mapped to the Schedule terms to avoid mislabelling.
7. Prohibition of certain labels and leaflets (Regulation 6)
Regulation 6 is the Regulations’ anti-misrepresentation core. It prohibits:
- Container/package claims: no person may sell or supply a Chinese proprietary medicine if the container or package contains any statement or representation that (directly or indirectly) claims, indicates, or suggests the medicine will prevent, alleviate, or cure any disease or condition specified in the First Schedule to the Medicines Act.
- Leaflet claims: no person may supply (or possess for supply) any leaflet containing similar prohibited statements/representations.
For legal practitioners, this is often the most contentious compliance issue because marketing language, translations, and even implied claims can be scrutinised. The prohibition is not limited to explicit wording; it covers indirect suggestions.
Note: The extract truncates the remainder of Regulation 7 (“Manner in which particulars are to be stated”) and later provisions (including language requirements and additional information). However, the structure of the Regulations indicates further detailed rules on formatting, presentation, and language, which are typically essential for full compliance review.
How Is This Legislation Structured?
The Regulations are organised as follows:
- Regulation 1: Citation.
- Regulation 2: Definitions (including “appropriate non-proprietary name” and “appropriate quantitative particulars”).
- Regulation 2A: Scope/exclusion for clinical research material.
- Regulation 3: Mandatory particulars to be shown on container, package, and leaflet, including exceptions and practical packaging scenarios.
- Regulation 4: Deleted (as reflected in the current version timeline).
- Regulation 5: Labelling requirement for substances listed in the Schedule, with English statements.
- Regulation 6: Prohibition of certain labels and leaflets (disease prevention/alleviation/cure claims for diseases/conditions in the First Schedule to the Medicines Act).
- Regulations 7–9: Rules on how particulars must be stated, language requirements, and additional information to be shown (not fully reproduced in the extract).
- The Schedule: Substances to be labelled.
In addition, the legislative history shows amendments over time, including a key amendment effective 1 November 2016 (S 546/2016) that introduced the clinical research exclusion (Regulation 2A) and deleted Regulation 4.
Who Does This Legislation Apply To?
The Regulations apply to “any person” involved in the sale or supply of Chinese proprietary medicines in Singapore. This includes manufacturers, wholesalers, importers, retailers, and distributors who place products on the market or supply them to consumers.
Because Regulation 3 imposes obligations on the act of sale or supply, compliance is not limited to manufacturers alone. A wholesaler or importer may be exposed if the product is distributed with non-compliant labels or leaflets. Similarly, a retailer may face liability if it sells a medicine whose container/package/leaflet fails to meet the statutory requirements.
Why Is This Legislation Important?
First, the Regulations operationalise consumer protection through labelling. They require a structured set of information—identity, ingredients, dosage, intended use, contraindications (“should not be used” purposes), side effects, and directions for administration. This supports informed decision-making and reduces the risk of misuse.
Second, the Regulations create enforceable boundaries around therapeutic claims. Regulation 6’s prohibition on disease prevention/alleviation/cure claims for diseases/conditions specified in the Medicines Act’s First Schedule is a key legal safeguard against misleading advertising and unapproved therapeutic claims. In practice, this affects how companies translate and market traditional claims, and how they design packaging and leaflets for Singapore.
Third, the Regulations have direct compliance implications for documentation and artwork control. Practitioners advising regulated entities should consider implementing a label compliance workflow that verifies: (i) the correct non-proprietary names and quantitative ingredient particulars (or a properly supported secret/protected formula exception); (ii) the correct English Schedule substance declarations; and (iii) that no prohibited disease-related claims appear on container, package, or leaflet—whether explicit or implied.
Related Legislation
- Medicines Act (Chapter 176), including Sections 44, 45, 46 and 52 (authorising provisions) and the First Schedule to the Act (disease/condition list referenced in Regulation 6)
- Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 (G.N. No. S 336/2016) — definition of clinical research material referenced in Regulation 2A
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (O 6) — definition of “Chinese proprietary medicine” referenced in Regulation 2
Source Documents
This article provides an overview of the Medicines (Labelling of Chinese Proprietary Medicines) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.